SEC Form 4 · accession 0001127602-17-003938
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Young
Officer — Chief Operating Officer
Period of report
Feb 1, 2017
Accepted (ET)
Feb 3, 2017 · 5:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2017 | M | 620 | $0.00 | A | 2,190 | D | |
| Common Stock | Feb 1, 2017 | F | 215 | $72.82 | D | 1,975 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 1, 2017 | M | 620 | D | — | — | Common Stock | 620 | 6,530 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F2The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.